Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population

Singapore Medical Journal

Volumn 47, Issue 6, 2006, Pages 534-542

  Nadarajah, A ^a   Abrahan, L ^b   Lau, F L ^c   Hwang, L J ^d   Fakir Bolte, C ^d  

^a 94 Armed Forces Hospital   (Malaysia)

^b Philippine Heart Centre   (Philippines)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^d PFIZER INC   (United States)

Author keywords

Ankle sprain; Celecoxib; Diclofenac SR; Drug efficacy; Musculoskeletal injuries

Indexed keywords

CELECOXIB; DICLOFENAC;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANKLE SPRAIN; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SOMNOLENCE; STATISTICAL ANALYSIS; VISUAL ANALOG SCALE; WEIGHT BEARING;

ACUTE DISEASE; ADULT; ANKLE INJURIES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIA; BLOOD PLATELETS; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DICLOFENAC; FEMALE; HUMANS; MALE; PAIN MEASUREMENT; PYRAZOLES; SPRAINS AND STRAINS; SULFONAMIDES; TREATMENT OUTCOME; WEIGHT-BEARING;

EID: 33745125683     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Kannus P, Renstrom P. Treatment for acute tears of the lateral ligaments of the ankle. Operation, cost, or early controlled mobilization. J Bone Joint Surg 1991; 73:305-12.
2. Liu SH, Nguyen TM. Ankle sprains and other soft tissue injuries. Curr Opin Rheumatol 1999; 11:132-7.
3. Liu SH, Jason WJ. Lateral ankle sprains and instability problems. Clin Sports Med 1994; 13:793-809.
4. Colville MR, Amendola N, Butters MA, et al. Clinical Guideline on Ankle Injury. Rosemont, IL: American Academy of Orthopaedic Surgeons, 1999.
5. Bahamonde LA, Saavedra H. Comparison of the analgesic and antiinflammatory effects of diclofenac potassium versus piroxicam versus placebo in ankle sprain patients. J Int Med Res 1990; 18:104-11.
6. Morán M. Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res 1991; 19:121-30.
7. Heere LP. Piroxicam in acute musculoskeletal disorders and sports injuries. Am J Med 1988; 84(Suppl 5A):50-5.
8. McIlwain HH, Platt RD. Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes. Am J Med 1988; 84(Suppl 5A):56-60.
9. Slatyer MA, Hensley MJ, Lopert R. A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian regular army recruits. The Kapooka Ankle Sprain Study. Am J Sports Med 1997; 25:544-53.
10. Dreiser RL, Riebenfeld D. A double-blind study of the efficacy of nimesulide in the treatment of ankle sprain in comparison with placebo. Drugs 1993; 46(Suppl 1):183-6.
11. Calligaris A, Scaricabarozzi I, Vecchiet L. A multicentre double-blind investigation comparing nimesulide and naproxen in the treatment of minor sports injuries. Drugs 1993; 46(Suppl 1):187-90.
12. McLatchie GR, Allister C, MacEwen C, et al. Variable schedules of ibuprofen for ankle sprains. Br J Sports Med 1985; 19:203-6.
13. Campbell J, Dunn T. Evaluation of topical ibuprofen cream in the treatment of acute ankle sprains. J Accid Emerg Med 1994; 11:178-82.
14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-5.
15. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-7.
16. Otto JC, Smith WL. Prostaglandin endoperoxide synthases-1 and -2. J Lipid Mediat Cell Signal 1995; 12:139-56.
17. Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand J Rheumatol 1996; 25(Suppl 102):23-8.
18. Simon LS. Nonsteroidal antiinflammatory drugs and their effects. The importance of COX "selectivity." J Clin Rheumatol 1996; 2:135-40.
19. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343:769-72.
20. Erratum in: Lancet 1994; 343:1048.
21. Comment in: Lancet 1994; 344:56-7.
22. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-8.
23. Erratum in: Lancet 1994; 343:1302.
24. Comment in: Lancet 1994; 343:1051-2,
25. Lancet 1994; 344:56-7.
26. Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33-9.
27. Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology 2003; 42:1207-15.
28. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2 selective inhibitors. Cleve Clin J Med 2002; 69(Suppl 1):SI31-9.
29. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40:124-32.
30. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282:1921-8.
31. Comment in: JAMA 1999; 282:1961-3,
32. JAMA 2000; 283:1961-2.
33. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27:1876-83.
34. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005; 7:R644-65.
35. Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop 2002; 31:445-51.
36. Petrella R, Ekman EF, Schuller R, Fort JG. Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial. Clin J Sport Med 2004; 14:225-31.
37. Comment in: Clin J Sports Med 2005; 15:196-7.
38. Yepes JP, Ekman E, Levy SD, Fort JG. Efficacy of celecoxib versus diclofenac in the treatment of pain associated with acute ankle sprain: a multicenter, doubleblind, randomized controlled trial. Ann Rheum Dis 2002; 61 (Suppl 1):abstract ABO507.
39. Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med 2003; 4:277-94.
40. Erratum in: Pain Med 2005; 6:99.
41. Comment in: Pain Med 2003; 4:211-2.
42. Lasch KE. Culture, pain, and culturally sensitive pain care. Pain Manag Nurs 2000; 1(3 Suppl 1):16-22.
43. Edwards RR, Fillingim RB. Ethnic differences in thermal pain responses. Psychosom Med 1999; 61:346-54.
44. Gerber JP, Williams GN, Scoville CR, Arciero RA, Taylor DC. Persistent disability associated with ankle sprains: a prospective examination of an athletic population. Foot Ankle Int 1998; 19:653-60.
45. Verhagen RAW, de Keizer G, van Dijk CN. Long-term follow-up of inversion trauma of the ankle. Arch Orthop Trauma Surg 1995; 114:92-6.
46. Yeung MS, Chan KM, So CH, Yuan WY. An epidemiological study on ankle sprain. Br J Sports Med 1994; 28:112-6.
47. Renstrom PA, Konradsen L. Ankle ligament injuries. Br J Sports Med 1997; 31:11-20.
48. Ogilvie-Harris DJ, Gilbart M. Treatment modalities for soft tissue injuries of the ankle: a critical review. Clin J Sport Med 1995; 5:175-86.
49. Weiler JM. Medical modifiers of sports injury. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in sports soft-tissue injury. Clin Sports Med 1992; 11:625-44.
50. Green D, Davies RO, Holmes GI, et al. Effects of diflunisal on platelet function and fecal blood loss. Clin Pharmacol Ther 1981; 30:378-84.
51. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35:209-19.
52. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119:255-66.
53. Scheiman JM, Cryer B, Kimmey MB, et al. A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin Gastroenterol Hepatol 2004; 2:290-5.
54. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3:133-41.
55. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs. BMJ 2002; 325:624.
56. Comment in: BMJ 2002; 325:607-8.